Updated on 28 September 2026
NaDeNo Series A | Drug delivery platform and PACAB-002 for ovarian cancer
About
NaDeNo is raising a €15m Series A to advance PACAB-002, our lead platform-enabled candidate for eradicating peritoneal micrometastases in ovarian cancer, through clinical development and to expand our drug delivery platform with several pipeline projects.
NaDeNo has a differentiated and versatile drug delivery platform and a clear first clinical application with strong momentum.
Major points of traction:
-
PACAB-002 is on track to start Phase 1 in early 2027.
-
NaDeNo has received €10m in blended finance from the EIC Accelerator program.
-
Our platform is expanding through active collaborations, including work on oral delivery with AstraZeneca.
Similar opportunities
Investment
- Startup
- Healthcare
- Biotech, Pharma and Cosmetics